atezolizumab,cabozantinib
roche,exelixis
['cosmic-021', 'urothelial', 'atezo', 'cabozantinib']
asco 2022 news: fresh data from cosmic-021 point to the promise of cabozantinib atezolizumab in untreated and ici-treated advanced urothelial cancer.
Springer Healthcare IME, providing independent medical education in Neurology, Diabetes, Oncology, Rare Diseases, Endocrinology, and Paediatrics.